Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2013 1
2018 7
2019 7
2020 6
2021 12
2022 17
2023 16
2024 17
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.
Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Miliziano D, Menichetti A, Ligorio F, Zurlo C, Griguolo G, Berton Giachetti PP, Faso V, Corti C, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruneri G, Mariani L, Vernieri C; PALMARES-2 Study Group. Provenzano L, et al. Ann Oncol. 2025 Jul;36(7):762-774. doi: 10.1016/j.annonc.2025.03.023. Epub 2025 Apr 8. Ann Oncol. 2025. PMID: 40204155 Free article.
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.
Terzolo M, Fassnacht M, Perotti P, Libé R, Kastelan D, Lacroix A, Arlt W, Haak HR, Loli P, Decoudier B, Lasolle H, Quinkler M, Haissaguerre M, Chabre O, Caron P, Stigliano A, Giordano R, Zatelli MC, Bancos I, Fragoso MCBV, Canu L, Luconi M, Puglisi S, Basile V, Reimondo G, Kroiss M, Megerle F, Hahner S, Kimpel O, Dusek T, Nölting S, Bourdeau I, Chortis V, Ettaieb MH, Cosentini D, Grisanti S, Baudin E, Berchialla P, Bovis F, Sormani MP, Bruzzi P, Beuschlein F, Bertherat J, Berruti A. Terzolo M, et al. Among authors: cosentini d. Lancet Diabetes Endocrinol. 2023 Oct;11(10):720-730. doi: 10.1016/S2213-8587(23)00193-6. Epub 2023 Aug 21. Lancet Diabetes Endocrinol. 2023. PMID: 37619579 Free PMC article. Clinical Trial.
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
Baudin E, Goichot B, Berruti A, Hadoux J, Moalla S, Laboureau S, Nölting S, de la Fouchardière C, Kienitz T, Deutschbein T, Zovato S, Amar L, Haissaguerre M, Timmers H, Niccoli P, Faggiano A, Angokai M, Lamartina L, Luca F, Cosentini D, Hahner S, Beuschlein F, Attard M, Texier M, Fassnacht M; ENDOCAN-COMETE; ENSAT Networks. Baudin E, et al. Among authors: cosentini d. Lancet. 2024 Mar 16;403(10431):1061-1070. doi: 10.1016/S0140-6736(23)02554-0. Epub 2024 Feb 22. Lancet. 2024. PMID: 38402886 Clinical Trial.
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives.
Zambelli A, Gerosa R, Cinquini M, Di Maio M, Miglietta F, Arecco L, Biganzoli L, Bernardi D, Cortesi L, Del Mastro L, Dieci MV, Foglietta J, Fortunato L, Franco P, Mantellini P, Marchiò C, Meduri B, Micallo G, Musolino A, Salvetti A, Santini D, Lanzetta G, Cosentini D, Bertoldo F, Cazzato RL, Cellini F, Denaro V, Di Martino A, Fusco V, Greco C, Ibrahim T, Maccauro G, DeFeo G, Severi S, Gori S. Zambelli A, et al. Among authors: cosentini d. Tumori. 2025 Oct;111(5):366-378. doi: 10.1177/03008916251367339. Epub 2025 Sep 15. Tumori. 2025. PMID: 40947910
Immunotherapy failure in adrenocortical cancer: where next?
Cosentini D, Grisanti S, Dalla Volta A, Laganà M, Fiorentini C, Perotti P, Sigala S, Berruti A. Cosentini D, et al. Endocr Connect. 2018 Dec;7(12):E5-E8. doi: 10.1530/EC-18-0398. Endocr Connect. 2018. PMID: 30400026 Free PMC article.
Adjuvant denosumab for early breast cancer-Evidence and controversy.
Moretti L, Richelmi L, Cosentini D, Pedersini R, Grisanti S, Amoroso V, Berruti A, Laganà M. Moretti L, et al. Among authors: cosentini d. Breast. 2024 Dec;78:103826. doi: 10.1016/j.breast.2024.103826. Epub 2024 Oct 23. Breast. 2024. PMID: 39509862 Free PMC article.
The Evolving Treatment Landscape of Medullary Thyroid Cancer.
Laganà M, Cremaschi V, Alberti A, Vodopivec Kuri DM, Cosentini D, Berruti A. Laganà M, et al. Among authors: cosentini d. Curr Treat Options Oncol. 2023 Dec;24(12):1815-1832. doi: 10.1007/s11864-023-01145-5. Epub 2023 Nov 18. Curr Treat Options Oncol. 2023. PMID: 37979019 Free PMC article. Review.
Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma.
Laganà M, Habra MA, Remde H, Almeida MQ, Cosentini D, Pusceddu S, Grana CM, Corssmit EPM, Bongiovanni A, De Filpo G, Lim ES, Zamparini M, Grisanti S, Deutschbein T, Fassnacht M, Fagundes GFC, Pereira MAA, Oldani S, Rota S, Prinzi N, Jimenez C, Berruti A. Laganà M, et al. Among authors: cosentini d. Eur J Cancer. 2024 Sep;208:114122. doi: 10.1016/j.ejca.2024.114122. Epub 2024 Jul 3. Eur J Cancer. 2024. PMID: 39047533 Free article.
81 results